Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

FDA Approves US Clinical Trials to Treat ALS with Israel Stem Cell Technology

The United States Food and Drug Administration (FDA) has approved the start of multi-center Phase II clinical trials in the United States to treat amyotrophic lateral sclerosis (ALS) with adult stem cell technology first introduced by the Hadassah Medical Organization’s Prof. Dimitrios Karussis, Senior Neurologist and head of Hadassah’s Multiple Sclerosis Center.

The treatment, developed by Israel’s BrainStorm Cell Therapeutics, involves injecting autologous stem cells (coming from the patients themselves) into the spinal fluid. Earlier clinical trials at Hadassah have shown that the treatment was both well tolerated and safe. “Ten of the 15 patients in the Hadassah trials responded or stabilized,” reports Prof. Karussis, “and the disease was halted, with their breathing improved. About three of them even showed that the disease had receded, with them improving dramatically.” He notes, however, that the treatment is not a permanent cure. The injection “probably has to be repeated after several months.”

Trials will begin at Massachusetts General Hospital in Boston and the University of Massachusetts Memorial Hospital in Worcester and later be initiated at the Mayo Clinic in Minnesota.
Read more in The Jerusalem Post

Date: 4/30/2014

Hadassah’s Advanced Gene Sequencing Changes the Life of a Family from Uzbekistan

IDF Medic Heroically Battles Terrorist, Both Treated at Hadassah

Orthopedic Trauma Turns Tragedy into Innovation at Hadassah

On the Cutting-Edge of Melanoma Treatment: Hadassah’s Protocols and Research

Saving a Newborn from a Life Without Sight

Terrorist and Victim Sent to Hadassah's Hospitals After Third Attack in Two Weeks

Three Sent to Hadassah After Second Jerusalem Terror Attack of the Week

Clinical Trial of Hadassah-Developed Stem Cell Treatment for Macular Degeneration Gets Go-Ahead from FDA

“We Don’t Say ‘No’,” Hadassah Neurosurgeon Explains in Operating on 82-Year-Old Patient

Cutting-Edge Medicine and Research; a Role Model for Peace: A Briefing from the Hospital's Director General

4 Ways Hadassah Hospital is Preparing for Ebola—Just in Case

Hailing from 17 Countries: the 39th Graduation Class of Hadassah’s International Master of Public Health Program

At Hadassah, Four Recover, Two Tragically Perish After Light Rail Attack

Other Doctors Suggested Aborting the Baby. The Experts at Hadassah Knew Better.

Hadassah Doctor Receives International Prize for Medical Innovation

Hadassah Doctors Rescue Frostbitten Nepal Avalanche Victim

Thousands Mourn Loss of Young Israeli Hero

A Mysterious Case Sends a Family Searching for Cures, Finding Hadassah

Grateful Patients, Their Families, and Their Doctors Offer Thanks

Head of Hadassah's Hospital Addresses The Economist Health Care Forum



More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America